Clinical Laserthermia Systems and Soteria Medical enter strategic partnership
Lund, Sweden – Clinical Laserthermia Systems AB (publ) (CLS) today announces that the company has entered a strategic partnership with Dutch Soteria Medical BV to jointly market and sell the companies combined product portfolios for minimally invasive MRI-guided diagnostic and therapeutic prostate procedures, in markets outside the United States.
CLS and Soteria both develop, manufacture and sell image guided products that are used in diagnostic and therapeutic procedures in interventional urology and radiology. The companies products are complimentary of one another with clear benefits to users and patients. CLS and Soteria have therefor decided on a joint marketing and sale of a combined product portfolio. It is anticipated that such coordinated activities will include not only marketing and sales activities but also related support services.
"The benefits of our collaboration in MRI-guided biopsy and focal laser ablation treatment are many for men with suspected prostate cancer. Through our combined product offering these men can now be offered fast, precise and gentle minimally invasive prostate procedures by allowing medical teams to work with a highly standardized, and thus efficient workflow, in a common system that integrates well with the hospital's existing MRI scanners." says Dan J. Mogren, CEO of CLS.
"We look forward to our collaboration with CLS and, in a joint effort, be able to offer our existing and new customers a common platform for MRI-guided targeted prostate biopsies and tumor focal laser ablation, in their challenging task to effectively diagnose and treat the growing number of prostate cancer patients” says Jan Sabisch, CEO of Soteria Medical.
Contact:
Dan J. Mogren, CEO Clinical Laserthermia Systems AB (publ)
Tel: +46 – (0)705 – 90 11 40 E-mail: dan.mogren@clinicallaser.com
About CLS
Clinical Laserthermia Systems AB (publ), develops and sells the TRANBERG® | Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and used in studies for treatment imILT®, the Company’s interstitial laser thermotherapy for immunostimulant ablation with potential abscopal effects. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The certified Advisor (CA) is FNCA Sweden AB, Tel: +46 8 528 00 399. E-mail: info@fnca.se.
For more information about CLS, please visit the Company's website: clinicallaser.se
About Soteria Medical
Soteria Medical B.V. is a Spin Off from Radboud University in Nijmegen, The Netherlands. Many years of development and clinical research have resulted in a new approach to perform MRI guided interventions by utilizing a robotic device, which is fully MR-compatible and allows real time monitoring in the MRI scanner. The scope of the company is the development, production and sales of medical devices and instruments - specifically in the field of Magnetic Resonance Imaging (MRI) and MRI guided interventions. Soteria’s initial product is a robotic manipulator for MRI guided prostate biopsies and interventions - utilizing a newly developed and patented motor principle. Soteria’s innovations will benefit patients worldwide, especially patients with early-stage prostate cancer, who have not received sufficient diagnosis and treatment with the current standard of care.
More information about Soteria Medical B.V. can be found on the company's website: https://www.soteria-medical.com
This disclosure contains information that CLS is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 03-02-2023 08:00 CET.